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ABSTRACT 
AIM 
The overall aim of this thesis was to investigate the association between cannabis use and 
psychiatric disorders with emphasis on schizophrenia, other psychoses, depression and long 
term effects on mortality.  Specific objectives were to: 1) investigate the long-term risk of 
schizophrenia, and other psychoses including brief psychoses among users and non-users of 
cannabis, (2) assess the risk of depression among users and non-users of cannabis, (3) 
determinate whether schizophrenia patients with a history of cannabis use have a different 
prognosis, with regards to readmission and hospital duration, compared with those without a 
history of cannabis use, (4) assess the overall risk of death among cannabis users compared 
with non-users; and assess mortality among persons with psychotic disorders and find out to 
what extent cannabis use affects the excess mortality 
METHODS 
A Swedish cohort of 50 087 military conscripts with data on cannabis use recorded in 1969 
was followed up until 2007 (Study I, II, and III), and until 2011 (Study IV) in the Swedish 
National Patient Register and the Cause of Death Register as well as other socio-demographic 
databases. Information on a number of possible confounders were derived from the Swedish 
conscription cohort in 1969. Different statistical methods (cox proportional hazards models, 
negative binomial regression, logistic regression, multinomial logistic regression, and 
Fisher’s exact test) were used in this thesis.    
RESULTS 
(1) Heavy cannabis users remain with a higher risk of schizophrenia throughout the follow-up 
period compared to non-users. (2) After control for confounding factors and especially 
markers of disturbed behaviour during childhood, there was no increased risk of future 
depression among cannabis users. (3) Schizophrenia patients with a history of cannabis use 
had a significantly higher burden of in-patient care, with regard to hospital readmission and 
hospital duration, compared with those without a history of cannabis use. (4) Subjects with a 
history of heavy cannabis use are at higher risk of death compared with non-users. A history 
of cannabis use did not affect the increased mortality among persons with psychotic 
disorders. 
CONCLUSIONS 
It seems like the association between cannabis and schizophrenia may be stronger than that 
between cannabis and other psychiatric disorders such as brief psychosis and depression. Our 
findings indicate that the course and prognosis of schizophrenia may be more severe in 
cannabis users than schizophrenia cases in general. Subjects with a history of heavy cannabis 
use are at higher risk of long term psychotic effects as well as early death compared with non-
users. 
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1 Background 
 
1.1 Cannabis 
Cannabis is the most commonly used illicit drug among youth and young adults in both 
developed and developing countries (1). It is estimated that 124-203 million people use 
cannabis worldwide (2) with a prevalence peaked between 20-24 years of age. Cannabis 
dependence caused 2 million years lived with disability in 2010 (1).  
There is still greater uncertainty surrounding the estimates of cannabis use than of other 
drugs, such as cocaine or opioids, which is attributable to the scarcity of credible estimates of 
the prevalence of cannabis use in many countries (2). In some countries cannabis dependence 
produces more years lived with disability than drugs like amphetamines and cocaine, largely 
because the rate of cannabis use is higher than those of the stimulant drugs (1). Countries 
with the highest rate of burden of cannabis dependence are United States, Spain, France, and 
Australia (2, 3).  
In relation to cannabis use in Sweden, it is reported that in 1971, 16 % of girls and 14 % of 
boys in the 9th grade of compulsory school reported that they have used cannabis at least 
once. Only few years later, however, this percentage had dropped by more than half but in the 
1990s, however, the incidence of cannabis use rose once more, with percentage of 9th grade 
pupils who had used drugs at some point peaking in 2001 and 2010 (4). This might be 
interpreted as a general symptom of more liberal and individualistic attitudes towards 
cannabis and other drugs (5). In general, the level of use has been lower than in several other 
European countries and the USA (6-8).  
The life-time risk of dependence in cannabis users has been estimated at about 9%,  but rises 
to one in six among those who initiate use in adolescence (9). Consumption generally 
declines with age (10). However, about 10% of people who ever use cannabis, and one-third 
to half of those who use it daily, will become dependent on cannabis, and will use it despite 
having problems associated with its use (11). 
The main reason why most young people use cannabis is to experience a so-called high: mild 
euphoria, relaxation, and perceptual alterations, including time distortion and intensification 
of ordinary experiences such as eating, watching films, listening to music, and engaging in 
sex (9, 12).   
Cannabis is a generic term for preparations derived from the cannabis sativa plant (marijuana, 
hashish, and hash oil). The cannabis plant contains more than 60 unique cannabinoids. The 
one that is primarily responsible for the psychoactive effects is delta-9-tetrahydrocannabinol 
(THC). THC gives rise to transitory psychotic symptoms and impaired cognition in healthy 
volunteers; and, in people with a genetic risk of psychosis, an exaggerated psychotic response 
has been observed (13, 14) 
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In the human brain, the effects of the main psychoactive component of cannabis (THC) are 
mediated via cannabinoid CB1 (cannabinoid receptor type 1) receptors. CB1 receptors are 
one of the most common groups of receptors in the brain, and are widely distributed in the 
regions involved in cognition, memory, reward, pain perception, and motor coordination. 
They are found in basal ganglia, amygdala, the hippocampus, the cingulate cortex, and the 
molecular layer of the cerebellum. CB1 is generally known to suppress excitatory or 
inhibitory synaptic transmission. CB1 receptors are situated on presynaptic terminals that 
release neurotransmitters, such as glutamate and gamma-aminobutyric acid (GABA) (9, 14-
16). 
A shift in available cannabis preparations from resinous “hash” to intensively grown high 
potency herbal preparations, often referred to as skunk, took place in the late 1990s in 
developed countries, and the adverse health effects of these highly potent preparations are 
still unclear (17, 18). 
Not only the detrimental effects of high potent preparations of cannabis but also the long-
term adverse effects of cannabis are not well known.  A systematic review by Calabria et al 
(19) did not find sufficient evidence to determine an increased mortality among cannabis 
users compared to no users. They concluded that there is a need for long-term cohort studies 
that follow individuals into old age, when the probability of detrimental effects of cannabis 
use are more likely to emerge such as cancer, pulmonary diseases and coronary heart disease.  
What is known is that cannabis use is highly correlated with use of alcohol, tobacco, and 
other illicit drugs, all of which adversely affect health. Those at highest risk of cannabis 
dependence have a history of poor academic achievement, deviant behaviour in childhood 
and adolescence, rebelliousness, and poor parental relationships (9). There is also an 
extensive literature on the association between cannabis and mental health outcomes, but with 
important knowledge gaps that will be explored in this thesis 
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1.2 Psychosis 
Psychosis means a mental state involving loss of contact with reality with presence of 
delusions and/or hallucinations. It may include disordered thought or speech, behavioural 
disorganization, gross excitement and over activity (20). 
Psychosis exists in the general population as a continuous phenotype rather than as an all-or-
none phenomenon (21). Psychosis is not exclusive of schizophrenia and occurs in various 
diagnostic categories of other disorders including other non-affective psychoses and affective 
disorders such as bipolar and major depressive disorders.  
The criteria used to distinguish between these different categories of psychotic disorders are 
based on duration, dysfunction, associated substance use, and presence of depression or 
mania (22). 
Many people with diagnoses of other psychoses including non-affective and affective 
psychoses are later diagnosed with either schizophrenia or affective disorders e.g. bipolar 
disorder (23-25). Conversely, a number of patients with severe depression have psychotic 
features (26).  
1.2.1 Non-affective psychoses 
Schizophrenia 
Schizophrenia is a leading cause of disability worldwide (27) with the highest proportion 
occurring in men during young adulthood.  The rate ratio for males:females is 1.4:1 (28). 
Lifetime prevalence has been reported in the range of 0.5% to 1.6% (29). 
Schizophrenia is a rare and severe disabling disorder of unknown clear aetiology (30). 
Multiply risk factors including obstetric complications, some immigrant ethnic groups, urban 
life, advanced paternal age, positive family history, and cannabis use (22, 31) have been 
associated with an increased risk of developing schizophrenia. 
In most cases, schizophrenia is preceded by a prodromal phase that can be manifested as non-
specific clinical states, with depressive and anxiety symptoms (32), which can last up to 
several years (33, 34). These prodromal symptoms are non-specific of schizophrenia, and 
most people with these symptoms will not develop schizophrenia. 
The onset of Schizophrenia typically occurs between the late teens and the mid-30s, with 
onset prior to adolescence rare, and infrequently after the age of 45 years. Psychotic 
symptoms tend to be episodic over time, with their emergence or worsening associated with a 
potential risk to self or others, often requiring temporary hospitalization (35). Negative 
symptoms and cognitive problems tend to be more stable over time, and contribute 
significantly to functional impairment debilitating and deteriorating disorder with poor 
outcome (22).  
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Hallucinations and delusion have been consistently given as a diagnostic criteria for 
schizophrenia throughout the history of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) and International Classification of Diseases (ICD).  According to DSM V 
and ICD-11, Schizophrenia Spectrum and Other Primary Psychotic Disorders are defined by 
abnormalities in one or more of the following five domains: delusions, hallucinations, 
disorganized thinking (speech), grossly disorganized or abnormal motor behaviour (including 
catatonia), and negative symptoms, which occur with sufficient frequency and intensity to 
deviate from expected cultural or subcultural norms.  
The multiplicity of the clinical presentations of schizophrenia and the fact that its outcomes 
can range from full recovery to profound disability have confronted its credibility as a single 
disorder and more as heterogeneous disorder. As a result, there have been many attempts to 
define subtypes of schizophrenia which have a more uniform clinical picture which might 
show meaningful differences in prognosis, and facilitate identification of etiological factors of 
subtypes of schizophrenia (36). 
Prognosis is poor outcome in less than 50% of patients and, similarly, with good outcome in 
less than 50% of patients. Therefore, the course and outcome of schizophrenia is 
characterised by mainly unexplained heterogeneity rather than uniform poor outcome (37). 
Even in patients with good control of positive symptoms, return to function could remain a 
challenge. Few patients currently resume employment, and about a third, remain with a 
severe symptomatology (22). 
In the past 20 years, new agents, known as the second generation antipsychotics (clozapine, 
risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole) have been introduced for 
treatment. Although the new second-generation antipsychotic drugs are effective in treating 
positive symptoms with a reduced burden of motor side-effects, the promise of efficacy 
against negative and cognitive symptoms has not been borne out (38). Additionally, the new 
antipsychotics tend to induce a high incidence of metabolic side-effects (22). 
People with schizophrenia are at increased risk for premature death associated with comorbid 
somatic conditions (39) and high suicide rates (40, 41). Overall, People with schizophrenia 
have twice as high mortality rate compared with the general population (40-42). Several 
studies have suggested this mortality gap is unchanging and even widened over time after the 
inclusion of second generation antipsychotics (40, 41, 43).  It is sobering to reflect whether 
risk factors such as cannabis use could be an explanatory factor for this mortality gap. 
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Other non-affective psychoses 
Other non-affective psychoses such as brief psychosis are characterized by acute onset of 
psychotic symptoms that emerge without a prodrome and reach their maximal severity within 
weeks in individuals, in most of the cases the individuals have no history of another psychotic 
disorder. Symptoms may include delusions, hallucinations, disorganization of thought 
processes, perplexity or confusion, and disturbances of affect and mood. The duration of the 
episode rarely exceeds three months. 
Approximately 80% of developmental psychotic experiences are transitory and disappear 
over time. There is evidence, however, that transitory developmental expression of psychosis 
may become abnormally persistent and subsequently cause clinical impairment, depending on 
the degree of environmental risk the person is additionally exposed to (44). 
 
1.3 Depression 
One other important but much less often explored field of research is depression with 
psychotic features. Major depression with psychotic features is associated with greater illness 
severity compared with nonpsychotic major depression, as well as poorer prognosis, 
increased mortality, and distinct patterns of response to standard treatments for depression  
(45-47). 
While depressive symptoms are well recognized as forming part of the prodrome of 
schizophrenia, the presence of psychotic-like experiences in depression is less well 
understood (48). 
The evidence that cannabis use increases the risk of psychotic symptoms implies that there 
may also be associations between cannabis and affective disorders with psychotic features, 
such as schizoaffective and bipolar disorders.  
1.3.1 Affective psychoses 
Opinions differ about whether schizophrenia and affective disorders, specially bipolar 
disorder, are the clinical outcomes of entirely different processes, or whether these two 
disorders have more  identical processes (25) having a common environmental cause or a 
shared causative risk factor is responsible for part of each disorder. Epidemiological and 
genetic molecular studies have found evidence that schizophrenia and bipolar disorder share 
some common genetic causes [12,13]. An intermediate phenotype is schizoaffective disorder, 
which shares diagnostic features of both disorders (49, 50). Knowledge of the common 
causes of these disorders might be beneficial for research and clinical propose. There may 
also be other risk factors in common across these disorders, such as cannabis use. 
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1.4 Cannabis and Psychosis 
 
Cannabis is well known for psychogenic effect on the brain. Its ability to induce paranoia and 
acute psychotic reactions was noted as early as 1845 by the French psychiatrist Moreau de 
Tours (14).  In 1987, the Swedish conscription cohort 1969/70 was used for the first time to 
examine the association between cannabis and schizophrenia (51). This study was later 
refined by Zammit et al (2002) again showing an association between cannabis and 
schizophrenia (52), findings on the association between cannabis and schizophrenia spectrum 
disorders were replicated in other longitudinal studies in the Netherlands (53), Germany (54) 
and New Zealand (55, 56), as summarized in a systematic review by Moore et al (57). 
All these studies support the concept of temporality by showing that cannabis use preceded 
the diagnoses of psychosis which support a causal relationship. Further evidence for causal 
association is provided by the presence of a dose-response relationship between cannabis and 
schizophrenia (58). In addition, the association persisted after controlling for many potential 
confounding factors such as disturbed behaviour, low IQ, place of upbringing, cigarette 
smoking, poor social integration, gender, age, ethic group, level of education, unemployment, 
single marital status and previous psychotic symptoms (58). On the other hand residual 
confounding by for example prodromal symptoms or personality traits associated with both 
cannabis use and an increased vulnerability for psychoses cannot be ruled out. The ongoing 
concern, about whether the association is causal or not, is still of great importance for public 
health as well as scientific (59, 60).  
The substantial variation in the incidence across places and minority groups, suggests that 
environmental factors such as cannabis use may have an important role (13). However, it has 
been demonstrated that the incidence rates of schizophrenia are rather decreasing than 
increasing whereas the cannabis use is increasing for example in UK (8). However, as there 
are many different risk factors operating at the same time (e.g. migration, advanced parental 
age, social adversity, and perinatal complications) and comparable incidence estimates are 
difficult to obtain, it is difficult to draw any conclusions. 
 
1.4.1 Possible explanations of the observed association 
One hypothesis postulating the strongest form of causal link is that heavy cannabis use cause 
a psychosis that would not otherwise have occurred (61, 62). A second hypothesis is the 
“Stress-vulnerability model of etiological” which assumes that genetic factors operate by 
making individuals selectively vulnerable for environmental risk. The neurodevelopmental 
model of schizophrenia (63), which posits that the illness is the end state of abnormal 
neurodevelopmental process that started years before the illness onset, supports the 
endocannabinoid hypothesis of schizophrenia. Endocannabinoid signalling is present during 
gestation, and early infancy and plays a critical role in neuronal proliferation, migration, 
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axonal guidance, positioning of cortical interneurons, and synaptogenesis, the 
neurodevelopmental role of this system continues during adolescence when regions such as 
hippocampus and prefrontal cortex are still undergoing marked development (64-66).  
It has been hypothesized that repeated exposure to cannabis during adolescence and young 
adulthood may cause permanent dysregulation of the dopaminergic and GABA system 
development (67) and impaired neural connectivity (68).  
Most of the work on neurobiology of psychotic syndrome to date has focused on alterations 
in glutamate, dopamine and GABAergic system. 
The effects of the main psychoactive component of cannabis (THC) are mediated via 
cannabinoid CB1 receptors (15, 16). THC may increases dopamine release, although THC 
may not induce a significant increase dopamine in healthy volunteers, it does so in patients 
with schizophrenia and their relatives, implying that a genetic vulnerability to react in an 
exaggerated manner to cannabis (69-71). Animal experiment has showed that CB1 receptor 
stimulation impairs GABA functioning (72), and it has been also showed that exogenous 
cannabinoids such as THC can also lead to decreased GABA release (73, 74).  
Given that dopaminergic functioning is intertwined with, and regulated by, GABAergic, 
glutamatergic and endocannabinoid signalling, and that CB1 receptor activation enhances 
mixed synaptic transmission among these neurotransmitters (75), it is hypothesized that THC  
may induce psychotic syndrome through different pathways. 
 
1.4.2 Remaining questions and implications for research 
While evidence has grown stronger in recent years that use of cannabis in adolescence is 
associated with later risk of schizophrenia (57), several issues need to be clarified regarding 
this association. It is of clinical as well as public health importance to study whether the 
increased risk of schizophrenia varies over time, course of disease and mortality among 
schizophrenic patients with a history of cannabis use compared with those without, and 
whether cannabis use is also associated with other psychiatric disorders such as brief 
psychosis, depression, and risk of death. 
While it is also hypothesized that the adverse effects of cannabis use are most pronounced 
among adolescents and decline with increasing age, the long-term impact of cannabis use 
during adulthood and how the increased risk of schizophrenia associated with cannabis use 
varies over time is not known (11).The cumulative evidence suggests that earlier initiation of 
cannabis use increases the chance of becoming a daily or nearly daily user of cannabis (76, 
77) and this, in turn, increases the risk of becoming dependent on cannabis and use it despite 
experiencing problems (11, 76). 
The inclusion of cannabis-induced psychotic disorder in the ICD-10 and DSM-IV has also 
reinforced the idea of the importance of studying the association between cannabis use and 
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other affective and non-affective psychoses. Other psychoses such brief psychosis and 
cannabis-induced psychosis could be an early sign of schizophrenia rather than a distinct 
clinical entity (78). Views differ about whether an environmental factor such as cannabis use 
can be a common causative risk factor for schizophrenia, brief psychosis, and depression, or 
whether cannabis use is only associated with schizophrenia (25). Since the Swedish 
conscription cohort has power to assess the specific outcome schizophrenia, it is of scientific 
as well as clinical interest to find out to what extent cannabis is a risk factor for schizophrenia 
in particular, or if the association with cannabis use can be found for also other psychiatric 
disorders. 
In recent years, concerns have been raised by increasing rates of cannabis use and depression 
among young people in many countries. These have been paralleled by an increasing concern 
about suicide among young adults for which problematic drug use and depression are both 
risk factors (79). To date, two systematic reviews (57, 79) and one meta-analysis have (80) 
investigated the association between cannabis use and the development of depression. They 
found that longitudinal studies provided mixed evidence on the nature of the association 
between cannabis use and depression and that even though heavy cannabis use may increase 
depressive symptoms; this relationship may be explained by confounding factors.  They 
concluded that more longitudinal studies, particularly taking into account significant 
confounding factors, are needed. An earlier study from the conscript cohort did not find an 
increased risk of suicide among cannabis users (81). Given the strong association between 
severe depression and suicide, the association between cannabis and depression needs to be 
clarified. 
Several studies have addressed the effect of cannabis on the course of illness in patients with 
schizophrenia. Zammit et al. (82) reviewed longitudinal studies of people with psychosis and 
found that cannabis use was consistently associated with increased relapse or 
rehospitalisation, and poorer adherence to treatment. They noted, however, that many studies 
had limitations, such as lack of control for baseline severity, and confounding. In order to 
overcome methodological limitations, Foti et al. (83) followed 229 patients with 
schizophrenia for 10 years with the aim of examining the association between cannabis use 
and course of illness. They concluded that cannabis is associated with an adverse course of 
psychotic symptoms in schizophrenia, but that the association was bidirectional, i.e. psychotic 
symptoms also increased cannabis use. Thus, while there is substantial evidence on the role 
of cannabis in persons with established psychoses, it would be of clinical importance to know 
whether the course and outcome of schizophrenia differ in people with a history of cannabis 
use prior to the onset of schizophrenia compared with those without. 
Subjects with psychotic disorders including schizophrenia have two to three times higher 
mortality rates than those in the general population (40-42). With respect to cause of death, 
about 40% is explained by suicide and other unnatural causes, and approximately 60% of 
premature deaths are from natural causes as cardiovascular and pulmonary disease (40, 42). 
Several studies have suggested this mortality gap is unchanging and even widened over time 
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after the inclusion of second generation antipsychotics (40, 41, 43). The fact that cannabis use 
increases risk of psychosis in a dose-response fashion and that patients with psychosis who 
continue to use cannabis show more severe and persistent symptoms suggests that cannabis 
use might increase the risk of death among psychotic patients. Thus, it is still not known 
whether or not cannabis use does increase mortality in general. Also, it is important to find 
out whether or not previous cannabis use increases the already high mortality among 
psychotic patients. 
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2 Aim and Research questions 
 
2.1 Aim 
 
The overall aim of this thesis was to investigate the association between cannabis use and 
psychiatric disorders with emphasis on schizophrenia, other psychoses, depression and long 
term effects on mortality. 
2.2 Research questions 
 
1. Is there at long-term follow up an increased risk of schizophrenia and other 
psychoses among cannabis users compared with non-users?     
 
2. Is there an increased risk of depression among cannabis users compared with 
non-users?    
 
3. Do schizophrenia patients with a cannabis history have another prognosis, with 
regard to readmission and hospital duration, compared to those without a cannabis history? 
 
4. Is there a difference in mortality between psychotic patients with a history of 
cannabis use and those without a history of cannabis use? 
 
 
5. Is there a difference in mortality between Swedish conscripts with a history of 
cannabis use and those without a history of cannabis use? 
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3 Methods 
Table 1. Overview of the studies 
STUDY I II III IV 
Research 
Question 
Is there at long-term 
follow up an increased 
risk of schizophrenia and 
other psychoses among 
cannabis users compared 
with non-users?     
Is there an increased risk 
of depression among 
cannabis users compared 
with non-users?    
Do schizophrenia patients 
with a cannabis history 
have another prognosis 
compared to those 
without a cannabis 
history? 
What is the risk of death 
among the conscripts 
and psychotic patients? 
comparing cannabis 
users with non-users of 
cannabis 
Data source Swedish conscription cohort 1969/70 
Study 
design 
Cohort study Cohort study Cohort study Cohort study 
Follow-up 
period 
1973-2007 1973-2007 1973-2007 1969-2011 
 
Population 
 
41 943 conscripts 
 
45 087 conscripts 
357 subjects with a 
diagnosis of 
schizophrenia during the 
follow-up period among 
45 375 conscripts 
45 375 conscripts 
683 subjects with 
psychotic disorders 
Exposure 
variable 
Cannabis use at conscription 
Outcome 
variable 
First diagnosis of 
schizophrenia and brief 
psychosis throughout the 
follow-up period (four 
decades) 
First diagnosis of 
depression (unipolar, 
bipolar disorder and 
affective psychosis) , and 
schizoaffective disorder 
Prognosis of 
schizophrenia, with 
regards to readmission 
and hospital duration 
Overall risk of death 
among the conscripts, 
and risk of death among 
persons with psychotic 
disorders 
Covariates Psychiatric diagnosis at 
conscription, IQ score, 
disturbed behaviour, 
smoking, brought up in a 
city 
Prior personality 
disorders at conscription, 
IQ, disturbed behaviour 
in childhood, social 
adjustment, risky use of 
alcohol, smoking, early 
adulthood socioeconomic 
position, use of other 
drugs, brought up in a 
city 
Diagnosis of personality 
disorders at baseline, 
family socio-economic 
position, IQ score, civil 
status during follow-up, 
place of residence at 
conscription, risky use of 
alcohol at conscription, 
and use of other drugs. 
Contact with juvenile 
authorities, run away 
from home, truancy, 
smoking, solvents abuse, 
risky use of alcohol, 
psychiatric diagnosis, 
parents divorced, use of 
other drugs, use of 
intravenous drugs, and 
IQ score. 
Measures Odds ratio for first 
diagnosis of psychotic 
disorders 
Hazard ratio for  first 
diagnosis of depression , 
and schizoaffective 
Median, Odds ratio, and 
Rate ratio for readmission 
and hospital duration 
Hazard ratio of death in 
relation to cannabis use 
at conscription 
Analysis Logistic Regression Cox proportional hazard 
modelling 
Multinomial Logistic and 
Negative binomial 
Regression 
Cox proportional hazard 
modelling 
 17 
 
3.1 Study population and data 
 
3.1.1 Study population 
For the studies in this thesis, we linked the Swedish conscription cohort 1969/70 to other 
Swedish registers. In studies I, II and III, the Swedish conscription cohort 1969/70 was 
followed until 2007. For Study IV, we used versions of the inpatient register and other socio-
demographic databases updated until 2011.  
Of all 50 087 Swedish conscripts in 1969/70, over 93% were aged 18–19 years. Only 2–3% 
of men were exempted from conscription, mainly because of a severe mental or physical 
handicap or a congenital disorder. Around 10% of subjects had missing information on 
cannabis use. A total of 3 918 (8.6%) individuals died during the 42 years of follow-up. 
Conscription examination was compulsory for all young Swedish men until recently. 
However, the Swedish conscription cohort 1969/70 is the only one that has retained personal 
identification on matters related to drug use and other behavioral characteristics, thereby 
enabling record linkage with the Total Population Register, Population and Housing 
Censuses, the Inpatient Register, and the Swedish Cause of Death Register. 
 
3.1.2 Data bases used 
Swedish conscription cohort 1969/70 
The data used in this thesis were derived from the Swedish conscription cohort 1969/70, 
based on a nationwide survey of 50 087 Swedish men who were examined for compulsory 
military training during autumn 1969 to spring 1970.  
The conscription tests normally took place during the last year of high school (ages: 18-19 
years) and were completed during two days. The tests included a medical examination, 
various physical tests, cognitive tests, and two non-anonymous, self-report questionnaires. 
One was related to psychosomatic and social circumstances in childhood and adolescence, 
the other to substance use: narcotic drugs, alcohol, sniffing of solvents, and tobacco smoking. 
The conscripts were informed that participation in the questionnaires was independent of the 
rest of the examination, and would not affect selection or ranking (84). 
All conscripts undertook a structured interview by a psychologist, and were also screened for 
psychiatric symptoms. Those presenting psychiatric symptoms were referred to a psychiatrist, 
and any diagnosis was recorded according to the Swedish version of the International 
Classification of Diseases, 8th revision. 
 18 
 
Total Population Register 
Since 1968, Statistics Sweden holds a register of the total population based on information 
from the tax administration. The register includes data on immigration and emigration. 
 
Population and Housing Censuses 
Between 1960 and 1990 a compulsory population and housing census was performed every 
five years. The resulting register contains information about both individuals (occupation, 
education, civil status) and households (regarding number of individuals in each household). 
 
Inpatient Register 
The Swedish National Inpatient Register, which records all inpatient admissions to hospitals 
in Sweden, was used to identify hospital admissions since 1970. The Swedish register 
recorded approximately 83% of all psychiatric admissions in 1973, 97% in 1974–1983, and 
95% in 1984–1986, and has been virtually complete since 1987. 
 
Swedish Cause of Death Register 
The Swedish Cause of Death Register covers all deaths of residents of Sweden since 1961. 
The causes of death were recorded according to the International Classification of Diseases 
(ICD). ICD-8 was used from 1969, ICD-9 from 1987, and ICD-10 from 1997. 
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3.2 Exposure 
Information on cannabis use was obtained from the surveys at the time of conscription. 
Questions were asked whether the subjects had ever used drugs, which drugs they had ever 
used, the first drug used, the drug most commonly used, frequency of use, and the use of 
specific drugs taken from a pre-prepared list.  
Level of cannabis use was determined through a question on the number of occasions the 
subject had used cannabis: Never, Once, 2–4, 5–10, 11–50, >50. We compared outcomes for 
subjects having ever used cannabis (thereby including everyone who reported cannabis use in 
any of the use categories) with those who had never used cannabis, and also compared 
outcomes for those reporting the highest level of use (>50 times) with those who had never 
used cannabis. 
 
3.3 Outcomes 
1. Long-term risk of schizophrenia and other psychoses including brief psychosis 
(STUDY I) 
The primary outcomes of interest were first diagnosis of schizophrenia as well as 
other non-affective psychoses including brief psychosis throughout the follow-up 
period.  
 
2. Risk of depression including unipolar depression, bipolar disorder and affective 
psychosis (STUDY II) 
The primary outcome of interest was first diagnosis of depression (unipolar 
depression, bipolar disorder and affective psychosis). 
 
3. Prognosis of schizophrenia, with regard to readmission and hospital duration 
(STUDY III)  
We assessed the duration of first admission, total number of hospital days, and 
number of readmissions among patients with a diagnosis of schizophrenia. 
 
4. Risk of death among people with a psychotic disorder (STUDY IV)  
The primary outcome was mortality in subjects with psychotic disorder.  
 
5. Overall risk of death in the Swedish conscription cohort (STUDY IV) 
The primary outcome was mortality in the total cohort. 
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3.4 Covariates 
We selected potential confounding variables on the basis of prior research indicating that they 
are likely to be associated with both cannabis use and the different outcomes (52, 57, 79, 80, 
82, 85, 86). 
 
Contact with juvenile authorities 
Subjects were asked whether they had been in contact with the juvenile authorities: several 
times, sometimes, never. 
Run away from home 
Questionnaire information was available on whether the subjects had run away from home 
during childhood: two or more times, once, never. 
Truancy  
Data on truancy were based on self-reported information: once a week, once a month, once 
per term, occasionally. 
Smoking 
Smoking was based on questionnaire information, and categorized as:  >20 cigarettes/day,  
11-20 cigarettes/day,  6-10 cigarettes/day, 1-5 cigarettes/day,  non-smoking. 
Solvent abuse 
Solvents abuse was obtained from the questionnaire, and categorized as :  >10 times, 2 to 10 
times, once, never.  
Risky use of alcohol 
Risky use of alcohol was derived from questions on high consumption of alcohol: none 
versus at least one of the following indicators – consumption of at least 250g 100% 
alcohol/week; have taken an eye-opener during a hangover; have been apprehended for 
drunkenness; have reported being drunk often. 
Psychiatric diagnosis at conscription  
Psychiatric diagnosis at conscription was assessed by a psychiatrist, and categorized in this 
study as:  any versus none. 
Parents divorced 
Data on whether subjects had grown up with divorced parents was obtained from the 
questionnaire: yes or no. 
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Use of other drugs at conscription 
Information on use of other drugs was obtained from the questionnaire. The following types 
of drugs were specified:  preludin, amphetamine, lysergic acid diethylamide, morphine, 
mebumal, and opium. Use of other drugs was categorized as ever used versus never used 
Use of intravenous drugs 
Intravenous drug use was based on self-reported information from the questionnaires, and 
categorized as: several times, once, never. 
IQ score 
IQ score was obtained at time of conscription and based on four main subtests: verbal IQ, 
visuospatial ability, general knowledge, and mechanical ability. Results on the four subtests 
were aggregated to give an overall standardized intelligence score, ranging from 1 to 9 (< 74, 
74 to 81, 82 to 89, 90 to 95, 96 to 104, 105 to 110, 111 to 118, 119 to 126, > 126).  
Brought up in a city 
“Brought up in a city” was based on self-reported information on upbringing: any one of 
Sweden’s three large metropolitan areas (Stockholm, Gothenburg, Malmö) versus other 
areas. 
Family socio-economic position 
Information on family socio-economic position was based on Census 1960 on data on each 
conscript’s father’s occupation: non-manual (collapsed intermediate and high non-manual), 
low non-manual, manual (unskilled, skilled) and others (farmers, self-employed, 
unclassified). 
Early adulthood socioeconomic position 
“Early adulthood socioeconomic position (Early adulthood SEP)” was based on information 
from Statistics Sweden on occupation: 1) high/intermediate non-manual 2) low non-manual 
3) manual skill/unskilled 4) farmers/self-employed/ unclassified. 
Civil status during the follow-up 
Information on civil status was based on Census 1970, 1975, 1980, 1985 and 1990. We 
categorized as a dichotomous variable ever married versus never married. 
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3.5 Statistical analyses 
 
Cox proportional hazards modeling 
Cox proportional hazard modelling was used to assess the relative risk of developing 
depression in relation to cannabis use at conscription (Study II), and also the relative risk of 
death in relation to cannabis use at conscription (Study IV). We assessed the proportional 
hazard assumption between cannabis use and each outcome by using a Kaplan-Meier plot. 
Log-rank tests were used to test equality across strata. We tested the equality-across-strata of 
each individual confounder to explore whether or not to include it in the final model. The 
quality of each model was tested by running a logistic regression and applying Hosmer-
Lemeshow’s GOF test. 
 
Negative binomial regression 
Negative binomial regression was used in Study III to estimate rate ratios with 95% 
confidence intervals (CIs) for duration of first admission, total number of hospital days, and 
number of readmissions among subjects who had ever used cannabis compared with those 
who had never used cannabis. This method models count variables rather than dichotomous 
outcomes. Negative binomial regression was used instead of Poisson regression because of 
over-dispersion of variance relative to the mean during follow-up (87). 
 
Logistic and multinomial logistic regression 
Logistic regression was used to calculate odds ratios and 95% confidence intervals (CIs) for 
developing schizophrenia, brief psychosis and other non-affective psychoses among cannabis 
users, and to assess the risk of schizophrenia and brief psychosis by decade, from 1970 until 
2007 (Study I). Logistic regression refers specifically to a regression where the dependent 
variable is binary; in the case of more than two categories of the dependent variable, the 
regression is referred to as a multinomial logistic regression (Study III).  
 
Fisher’s exact test 
Differences in first pre-morbid psychiatric diagnosis of schizophrenia and type of 
schizophrenia at first admission were tested using Fisher’s exact test (Study III). Fisher's 
exact test is used when the intention is to conduct a chi-square test, but one or more cells in 
the contingency table have an expected frequency of five or less. 
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3.6 Ethical approval 
The data were treated according to recommendations of the Swedish Data Inspection Board. 
Permission to use the conscription database for research purposes and to perform the relevant 
record linkages was granted by the Stockholm Regional Ethical Review Board (dnr 121/84,  
dnr 10/86, dnr 188/91, dnr 2010/5:2). 
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4 Results 
4.1 Risk over time of schizophrenia and brief psychosis (Study I) 
People with the highest level of cannabis use showed an approximately four-fold increase in 
the odds of schizophrenia, and a two-fold increase in the odds of brief psychosis and other 
non-affective psychoses, compared with non-users. A dose-dependent association was found 
between frequency of cannabis use and risk of schizophrenia (p for trend <0.01). The dose–
response association was weaker for brief psychosis and other non-affective psychoses, 
although the p value for trend was significant in the case of brief psychosis 
As shown in Table 2, heavy cannabis users retained a higher risk of schizophrenia throughout 
the follow-up period compared with non-users.  The odds ratios for brief psychosis did not 
decline over the decades, but appeared actually to increase over time, particularly among 
people with the highest use, although this was based on a small number of cases and the CIs 
were wide. 
 
Table 2: Adjusted odds ratios for schizophrenia by decade of first admission. The 
category “Ever used cannabis” comprises all who reported cannabis use, including those 
who reported “> 50 times”. 
 
          
         * Diagnosis of psychiatric illness on conscription, disturbed behaviour,  
         low IQ score, brought up in city, cigarette smoking. 
 
 
 
 
 
 
 
 1970-1979 1980-1989 1990-1999 2000-2007 
 OR 
Adjusted* 
OR 
Adjusted* 
OR 
Adjusted* 
OR 
Adjusted* 
Never used 
cannabis 
1 1 1 1 
Ever used 
cannabis 
 
2.2 (1.4-3.3) 1.9 (1.1-3.5) 1.2 (0.5-2.8) 0.7 (0.2-3.0) 
>50 times 4.1 (2.2-7.6) 3.9 (1.6-9.4) 2.5 (0.7-9.0) 2.7 (0.5-14.0) 
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4.2 Risk of depression (unipolar depression, bipolar disorder and affective 
psychosis) (Study II) 
 
Table 3 shows hazard ratios for depression (any case of unipolar disorder, bipolar disorder 
and affective psychosis) by level of reported cannabis use. Only subjects with the highest 
level of cannabis use showed an increased crude hazard ratio for depression, but this 
association disappeared after adjustment for the confounders.  
Heaviest cannabis use (>50 times) was associated with an increased risk of unipolar 
depression (HR 1.8, 95% CI, 1.2-2.7), but this association was eliminated after adjustment for 
confounding. Disturbed behaviour in childhood was the confounder that most attenuated the 
hazard ratios. 
 
Table 3:  Hazard ratios for overall depression (any case of unipolar disorder, bipolar 
disorder and affective psychosis) by reported frequency of cannabis use 
Cannabis use No. exposed No. 
cases 
HR     Crude HR  adjusted* 
Never 39 978 990 1 1 
Once 1 202 28 0.9 (0.6-1.4) 0.9 (0.6-1.5) 
2–4  1 486 51 1.4 (1.1-1.9) 1.2 (0.8-1.8) 
5–10  839 24 1.2 (0.7-1.8) 1.1 (0.6-1.8) 
11–50  727 24 1.3 (0.8-1.9) 0.6 (0.3-1.2) 
>50  855 29 1.5 (1.0-2.2) 0.8 (0.4-1.5) 
TOTAL 45 087 1 146   
* Prior personality disorders at conscription, IQ, disturbed behaviour in childhood, poor 
social adjustment, risky use of alcohol, smoking, early adulthood socioeconomic position, use 
of other drugs, brought up in a city. 
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4.3 Prognosis of schizophrenia, with regard to readmission and hospital 
duration (Study III) 
Schizophrenia patients with a history of cannabis use showed a higher median duration of 
first hospital episode than those without (59 days v. 30 days). Patients with a history of 
cannabis use also had a higher median rate of readmission (10 times v. 4 times). Also, the 
total number of hospital days was higher in patients with a history of cannabis use compared 
with those without (547 days v. 184 days).  
Table 4 shows the distribution of numbers of hospital days after controlling for confounding 
factors. There was more than a two-fold increase in the odds of a hospital stay lasting more 
than 2 years (>730 days) in people who had used cannabis compared with those without 
cannabis use after controlling for confounding (adjusted OR= 2.4, 95% CI 1.1–7.4). 
Table 4. Odds ratio for total number of hospital days among schizophrenia patients 
 < 45 days 
 
46 to 179  
days 
180 to 729  
days 
>730  
days 
Never used cannabis 71 (27%) 63 (24%) 71 (27%) 56 (21%) 
Ever used cannabis  11 (19%) 12 (21%) 13 (22%) 22 (38%) 
Adjusted OR (95% CI)* 1 1.6 (0.6-4.2) 1.3 (0.5-3.7) 2.4 (1.1-7.4) 
 
Table 5 shows the distribution of numbers of readmissions after controlling for confounding 
factors. There was an almost four-fold increase in the odds of having more than 20 hospital 
readmissions in patients with a history of cannabis use compared with non-users. This was 
slightly reduced after adjustment for confounding (adjusted OR 3.1, 95% CI 1.3–7.3). 
Table 5. Odds ratio for number of re-admissions among schizophrenia patients 
 < 4  times 5 to 20 times >20 times 
Never used cannabis 138 (53%) 96 (37%) 27 (10%) 
Ever used cannabis  25 (43%) 16 (28%) 17 (29%) 
Adjusted OR (95% CI)* 1 0.8 (0.4-1.7) 3.1 (1.3-7.3) 
* Table 4 and 5 are adjusted for diagnosis of personality disorders at baseline, family 
socioeconomic position, IQ score at conscription, civil status during follow-up, place of 
residence at conscription, risky use of alcohol at conscription, and use of other drugs at 
conscription 
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4.4 Risk of death among people with psychotic disorders (Study IV) 
Subjects with a diagnosis of psychotic disorder had an increased risk of death compared with 
those without a diagnosis of psychotic disorder. We did not find that excess mortality was 
higher among subjects with a history of cannabis use (ever users: 3.8, 95% CI 2.8-5.0; heavy 
users: 3.8, 95% CI 2.6-6.2) compared with never users of cannabis (3.7, 95% CI 3.1-44). 
 
4.5 Overall risk of death in the Swedish conscription cohort (Study IV) 
Figure 1 shows the survival curve by age at death according to cannabis use/non-use (never 
users, ever users, and heavy users). Ever users as well as heavy users had an earlier age at 
death compared with non-users. The difference was statistically significant for both 
categories of users versus never users (Log-Rank test<0.001). All subjects reporting cannabis 
use had an increased hazard ratio for mortality. After adjustment for confounders, the 
association persisted only for heavy users (1.4, 95% CI 1.1-1.8) 
 
Figure 1. Survival curve by age at death according to cannabis use: never users vs. ever 
users and heavy users 
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5 Discussion 
This thesis aimed to contribute to a better understanding of the association between cannabis 
use and psychiatric disorders with emphasis on schizophrenia, other psychoses, depression 
and long term effects on mortality. 
 
Is there at long-term follow up an increased risk of schizophrenia and other psychoses among 
cannabis users compared with non-users?     
The thesis confirms the strong associations between cannabis and psychotic disorders, with a 
more than three-fold increased risk of schizophrenia, and two-fold increased risk of other 
psychotic outcomes in the most frequent cannabis users. It seems as if the association 
between cannabis and schizophrenia may be stronger than that between cannabis and other 
non-affective psychoses. 
We observed that heavy cannabis users retained a higher risk of schizophrenia throughout the 
follow-up period compared with non-users. This may indicate that heavy users continue using 
cannabis for a longer period. Heavy cannabis use during adolescence may also trigger 
persistent psychosis according to the ‘cannabis–psychosis persistence model’ presented by 
Kuepper et al. (88), The model postulates that cannabis, particularly, has an effect on 
persistent types of psychoses, such as schizophrenia, in a dose-response fashion. 
 
Is there an increased risk of depression among cannabis users compared with non-users?    
Our main finding was that, after control for confounders, especially markers of disturbed 
behaviour during childhood, there was no increased risk of severe depression among cannabis 
users at ages 18 to 20. However, the finding of a substantially increased risk of 
schizoaffective disorder among cannabis users is consistent with previous findings on the 
associations between cannabis and different schizophrenia-related disorders (57). 
Our results indicate that the association between cannabis use and subsequent severe 
depression is likely to be confounded by risk factors common to both, such as disturbed 
behaviour during childhood. Cannabis use is a biologically plausible contributory cause of 
schizophrenia. An association has also been found, albeit less consistently, between cannabis 
use and severe depression (57, 79, 80). More research is needed to explore whether there is 
any association between cannabis use and milder forms of depression. 
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Do schizophrenia patients with a cannabis history have another prognosis, with regard to 
readmission and hospital duration, compared to those without a cannabis history? 
Schizophrenia patients with a history of cannabis use faced a significantly higher burden of 
inpatient care, with regard to hospital readmission and hospital duration, compared with those 
without a history of cannabis use.  
There are a number of possible mechanisms that might explain the associations between 
cannabis use and increased relapses and poorer clinical outcomes in schizophrenia. It has 
been suggested that cannabis use can cause long-lasting dysregulation of the endogenous 
anandamide/cannabinoid system that mediates the effect of tetrahydrocannabinol within the 
brain (53). It has also been suggested that cannabis increases the number of cannabinoid 
receptors in the brain, causing increased vulnerability to repeated psychotic episodes (89). 
Cannabis use has also been found to correlate with poor compliance with medication in first-
episode schizophrenia (90-92). All of these factors may result in poorer outcomes. 
 
Is there a difference in mortality between psychotic patients with a history of cannabis use 
and those without a history of cannabis use? 
Although in this thesis we found that schizophrenia patients with a history of cannabis use 
faced a significantly higher burden of inpatient care, both psychiatric and somatic, we did not 
find that a history of cannabis use increased the risk of death in subjects with psychotic 
disorders. We were limited in this regard in that there are no data on treatment for psychotic 
disorders or substance abuse in the inpatient register. The introduction of second-generation 
antipsychotic agents during the 1990s may have decreased the risk of death among cannabis 
users, as has been suggested in a review by Wobrock et al. (93), where second-generation 
antipsychotic agents were found to have greater efficacy in reducing substance use compared 
with first-generation antipsychotic agents.  
 
Is there a difference in mortality between Swedish conscripts with a history of cannabis use 
and those without a history of cannabis use? 
We found in this long-term follow-up of male conscripts that subjects with a history of heavy 
cannabis use had significantly higher risk of death (40%) compared with those without a 
history of cannabis use. The association persisted after controlling for several possible 
confounders. 
The relation between cannabis use and cancer has been investigated in a number of reviews 
(94, 95). The existing literature concludes that the evidence is conflicting, but there is reason 
to suspect that cannabis use can cause some forms of cancer, e.g., lung cancer. In relation to 
cardiovascular fatalities related to cannabis use, the results indicate that cannabis may cause 
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death among individuals with existing vulnerability (96, 97), but more evidence is needed 
before any firm conclusion can be drawn. 
Cannabis use has also been associated with fatal collisions (98), and is a key element in the 
“gateway drug theory” that postulates that cannabis use can facilitate the subsequent misuse 
of other drugs (98), both of which can contribute to increasing the risk of death among users. 
Recent global-burden-of-disease studies (3, 61) have recognized a limitation to capturing 
some commons disorders, such as cannabis dependence, that may contribute to years of life 
lost to premature mortality. Increasing awareness of the negative effects of cannabis use and 
the inclusion of more specific diagnoses related to cannabis, such as cannabis-induced 
psychotic disorder in the ICD-10 and DSM-IV, can help to identify more adverse effects of 
cannabis use, which may contribute to years of life lost due to premature mortality. 
 
6 Methodological considerations 
 
The studies in this thesis have some major strengths: First, the Swedish conscript survey uses 
what to date is the largest and longest population-based cohort with data on cannabis use, and 
also on a number of social and personality background factors. Second, this is still the only 
population-based cohort with enough power to assess schizophrenia as a specific outcome, 
and also a broader range of schizophrenia-spectrum disorders. Third, we have a homogeneous 
study population, which enables analyses of the lifetime prognosis of schizophrenia in 
relation to background factors. 
Several methodological issues need to be taken into consideration. First, we are constrained 
by having data regarding use of cannabis only before conscription, it is possible that other 
risk factors after baseline influence our results such as risky behaviour, use of alcohol and use 
of other drugs. Second, only males were included. Since the incidence of schizophrenia, other 
psychoses and depression can vary between men and women, it would be valuable to assess 
the associations also in women. Third, identification of diagnoses of schizophrenia, other 
psychoses and depression was limited to cases in inpatient care, so our findings may not be 
applicable to milder forms of psychosis and depression that do not require hospitalization. 
Fourth, we are restricted by not having data regarding treatment for schizophrenia in the 
inpatient register and by the association of cannabis with decreased adherence to treatment. 
Further studies are needed in order to clarify whether adherence to treatment explains the 
association between cannabis use and a poorer clinical outcome in schizophrenia, as 
suggested by Miller et al. (90). Fifth, we are limited in that we did not have information in 
hereditary factors.  Studies suggesting interaction between cannabis and certain genes (99), 
e.g., the AKT1 gene (100) and the COMT gene (101), may help to explain the associations of 
cannabis with psychotic disorders. 
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Exposure 
The validity of self-reports on cannabis use can be questioned. Since such reports were part 
of conscription examination, it is possible that conscripts would under-report since drug use 
indicates deviant behaviour, but also that they might over-report in order to be exempted from 
compulsory military training. The prevalence of cannabis use in the age group is, however, 
consistent with those found in school and other surveys carried out in Sweden around that 
time (6).  
The validity of the data on cannabis use in the conscript surveys has been previously assessed 
to be adequate (102, 103). Further, we investigated the number of hospital admissions with a 
diagnosis of drug addiction during the follow-up period, and found a high correlation 
between level of cannabis use at conscription and later hospital admission for drug abuse. 
Outcomes 
Regarding the validity of diagnoses in Sweden’s National Inpatient Register, several studies 
have demonstrated adequate validity of the major psychiatric diagnoses used in 
epidemiological studies. Likewise, the diagnosis of schizophrenia in the inpatient register has 
been found to be valid (104, 105). 
We minimized the possibility of reverse causality by excluding individuals who had a history 
of psychiatric illness prior to 1973. In Study II, in order to avoid misclassification of 
outcomes, 11 subjects who had diagnoses of both depression and either schizoaffective 
disorder or schizophrenia during follow-up were also excluded. 
The diagnosis of schizoaffective disorder has questionable validity as a separate clinical 
entity (106), but is often made when psychotic features are prominent, so we regarded it as 
important for it to be analysed separately. In this category, we only included subjects with a 
diagnosis of schizoaffective disorder who did not also have a diagnosis of depression or 
schizophrenia during follow-up so as to minimize overlapping diagnoses. 
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7 Conclusions 
Our thesis confirms that there is a strong association between cannabis and schizophrenia. 
Heavy cannabis users retained a higher risk of schizophrenia throughout the follow-up period 
compared with non-users. 
After control for confounders, especially markers of disturbed behaviour during childhood, 
there was no increased risk of future depression among cannabis users. The evidence for a 
causal link between cannabis use and depression is less convincing that it is for psychotic 
disorders. 
Schizophrenia patients with a history of cannabis use faced a significantly higher burden of 
lifetime inpatient care than non-cannabis users. Not only does cannabis increase the risk of 
schizophrenia, but our findings also indicate that the course and prognosis of schizophrenia 
may be more severe among cannabis users than in schizophrenia cases in general. 
We found that people with a history of heavy cannabis use are at greater risk of premature 
death than non-users. But a history of cannabis use does not seem to lead to increased 
mortality among people with psychotic disorders. 
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8 Implications 
The long term effect of cannabis use is much discussed, partly because it is related to the 
political and ideological debate on the regulation of cannabis.  The liberalization of laws on 
cannabis use in some countries and states, in addition to the decreasing age of first-time 
cannabis users and the increasing use of high potency preparations are causes for public 
health concern (68).  
Arsenault et al. (58) and Zammit et al. (107) have estimated that elimination of all cannabis 
use would reduce the incidence of schizophrenia by between 8 and 13%. These estimates are 
also consistent with, somewhat conflicting, evidence to date on whether an increase in 
cannabis use is associated with increased incidence of psychotic disorders in the general 
population (108). Hikman et al. (8) have estimated that cannabis would be responsible for 
10% of new schizophrenia cases, rising to 25%, if light use of cannabis also carries the risk. 
However, recent estimates suggest that cannabis use as a risk factor for schizophrenia is not a 
major contributor to the population-level burden of disease due to the low prevalence of 
schizophrenia worldwide (1, 27). There are many different risk factors for schizophrenia 
operating at the same time (e.g. migration, advanced parental age, social adversity, perinatal 
complications) and comparable incidence estimates are difficult to obtain 
As policy shifts towards decriminalization of cannabis use, it is arguable to hypothesize that 
cannabis use may increase in the general population, especially among young adults. By 
extension, so will the number of individuals for whom there will be negative health 
consequences as pointed out in a recent review in the New England Journal of Medicine (68).  
Knowledge of the long-term effects of cannabis is important for many other reasons. They 
include cognitive effects, psychosocial effects such as early school-leaving, cancer, 
cardiovascular diseases, suicide, traffic accident, and dependence. Also, there is the 
therapeutic potential of cannabis. Thus, existing evidence is important for policy and it seems 
wise to further investigate the positive and negative health consequences of cannabis use.  
In particular, as pointed out in a recent paper in The Lancet (109), global health and education 
policy should have a greater focus on adolescence, when health outcomes can be shaped by 
the environment.  
Even if schizophrenia is not a very frequent disease, it is among the most burdensome and 
costly illnesses worldwide (29). In the absence of better treatments for schizophrenia, one of 
the most effective ways of reducing the disability associated with schizophrenia would be to 
prevent the increasing number of cases associated with cannabis use. 
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